Editorial Material
Multidisciplinary Sciences
Alexander J. Gates, Deisy Morselli Gysi, Manolis Kellis, Albert-Laszlo Barabasi
Summary: The new analysis examines the impact of the draft genome on genomics since 2001, highlighting its effects on publications, drug approvals, and understanding of diseases.
Article
Biology
Chaohui Bao, Leyao Gu, Shan Wang, Kexin Zou, Zhiqiang Zhang, Lulu Jiang, Liye Chen, Hai Fang
Summary: Asthma is a chronic disease affected by genetic risks and environmental triggers, and can impact both adults and children. This study introduces a genetic and network-driven drug target prioritization tool called PIA, which improves drug target prioritization for asthma and identifies shared and distinct pathway crosstalk genes, providing potential therapeutic strategies for different subtypes of asthma.
COMPUTERS IN BIOLOGY AND MEDICINE
(2023)
Review
Oncology
Karl Heilbron, Sahar Mozaffari, Vladimir Vacic, Peng Yue, Wei Wang, Jingchunzi Shi, Adrian M. Jubb, Steven J. Pitts, Xin Wang
Summary: Human genetics is increasingly important in drug development and population health. It accelerates therapy discovery, provides evidence for successful drug targets, and discusses the benefits of polygenic risk scores in various clinical settings. Direct-to-consumer platforms and diverse genetic health data can benefit society in the era of fast-paced big data biotechnology.
JOURNAL OF PATHOLOGY
(2021)
Review
Infectious Diseases
Lan-Gui Song, Qing-Xing Xie, Hui-Lin Lao, Zhi-Yue Lv
Summary: This review provides an overview of drug development against HCoVs, particularly SARS-CoV-2, highlighting advancements in antiviral drugs, drugs targeting the host's immune response, and plant-derived drugs. Clinical trials targeting SARS-CoV-2 are also discussed. Efforts are being made to study the efficacy and safety of potential drugs to better control the COVID-19 pandemic.
INFECTIOUS DISEASES OF POVERTY
(2021)
Article
Microbiology
Annelies Van den Bergh, Patrice Guillon, Mark von Itzstein, Benjamin Bailly, Larissa Dirr
Summary: This study developed an in vitro medium-throughput screening assay to identify novel anti-HMPV drug candidates. Out of 2,400 compounds, 11 candidates were identified with inhibitory activity against HMPV infection. The mode of action of five candidates with low cytotoxicity was further described. Among them, the mycophenolic acid series displayed the highest levels of inhibition. It has significant potential for drug repurposing.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Margit Rosner, Manuel Reithofer, Dieter Fink, Markus Hengstschlaeger
Summary: Model systems are crucial for studying the molecular mechanisms of human diseases, with animal models and transformed cell lines playing important roles. However, limitations such as species-specific differences and the suitability of immortalized cell lines for normal human cells exist. Advances in human pluripotent stem cell research and 3D organoid technologies offer new possibilities for more accurate disease modeling in vitro.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Clinical Neurology
C. M. Diaz-Caneja, MW State, R. J. Hagerman, S. Jacquemont, O. Marin, C. Bagni, D. Umbricht, E. Simonoff, F. de Andres-Trelles, A. Kaale, G. Pandina, B. Gomez-Mancilla, P. P. Wang, J. Cusak, S. Siafis, S. Leucht, M. Parellada, E. Loth, T. Charman, J. K. Buitelaar, D. Murphy, C. Arango
Summary: In the field of neurodevelopmental disorders, multidisciplinary translational consortia developing basic and clinical research concurrently, especially incorporating a developmental perspective into the drug development process, may help overcome current challenges in identifying and testing new treatments.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
News Item
Multidisciplinary Sciences
Diana Kwon
Summary: Drugs that silence faulty genes could potentially treat brain diseases, but a halted clinical trial has posed a setback in this field.
Review
Cell Biology
Hidenori Tani, Shugo Tohyama
Summary: The emergence of human induced pluripotent stem cells (hiPSCs) and efficient differentiation of hiPSC-derived cardiomyocytes (hiPSC-CMs) have the potential to replicate the features of the human heart. Although the immaturity of hiPSC-CMs poses a challenge, various strategies have been effective in promoting maturation. Three-dimensional cardiac models and disease models using patient-specific hiPSC-CMs have enhanced our understanding of cardiac diseases and therapies. Besides disease mechanisms and drug responses, hiPSC-CMs can also be used for drug evaluation and predicting drug risk. This review discusses the current strategies and future applications of hiPSC-CMs for disease modeling, drug development, clinical trials, and cardiotoxicity tests.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yihui Song, Xiaoke Yang, Bin Yu
Summary: Drug repurposing is an attractive strategy for finding new indications for existing drugs. Three approved antidepressants have shown potential in clinical trials for cancer treatment. By conducting further medicinal chemistry research, several TCP-based inhibitors of the histone lysine specific demethylase 1 enzyme have been discovered, showing promise for cancer treatment. Repurposing antidepressants could be a promising strategy for cancer treatment.
DRUG DISCOVERY TODAY
(2022)
Review
Oncology
Pedro Reimunde, Alba Pensado-Lopez, Martin Carreira Crende, Vanesa Lombao Iglesias, Laura Sanchez, Marta Torrecilla-Parra, Cristina M. Ramirez, Clement Anfray, Fernando Torres Andon
Summary: Glioblastoma (GBM) is a highly challenging brain tumor with poor prognosis and limited treatment options. Research on cellular heterogeneity and genetic alterations has led to the development of zebrafish models for studying GBM physiopathology and testing new drugs, offering hope for improved diagnosis and treatment outcomes.
Article
Parasitology
Philip T. LoVerde, Sevan N. Alwan, Alexander B. Taylor, Jayce Rhodes, Frederic Chevalier, Timothy JC. Anderson, Stanton F. McHardy
Summary: Human schistosomiasis is a debilitating disease affecting millions globally, with drug resistance being a major concern. Scientists have identified novel drug derivatives effective against all species of the parasite, aiming to combat resistance and improve treatment outcomes.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE
(2021)
Review
Virology
Rima Hajjo, Dima A. A. Sabbah, Osama H. H. Abusara, Reham Kharmah, Sanaa Bardaweel
Summary: Despite advances in fighting viral diseases, new therapies are still lacking and existing antivirals have limitations. Host-targeted antivirals (HTAs) are emerging as promising alternatives to directly acting antiviral (DAA) drugs. HTAs target host proteins and have a broader spectrum and lower potential for resistance.
Review
Cardiac & Cardiovascular Systems
David H. Yoo, Rolf Bodmer, Karen Ocorr, Christopher J. Larson, Alexandre R. Colas, Evan D. Muse
Summary: Understanding the genetic contributions to AF is crucial for personalized risk stratification and drug discovery, but current polygenic risk scores have limitations that require further research and improvement. By integrating digital health tools, artificial intelligence, and genomic-driven drug discovery, a sophisticated level of precision medicine can be delivered in the modern era of emphasis on prevention.
CURRENT CARDIOLOGY REPORTS
(2021)
Review
Immunology
Francesca G. G. Tomasi, Eric J. J. Rubin
Summary: Despite significant advancements in the 20th century, tuberculosis (TB) remains a global health challenge, exacerbated by the COVID-19 pandemic. Improving TB chemotherapy through genetic and analytical tools can help identify and prioritize drug targets, leading to the rational design of treatment regimens that maximize bacterial killing and minimize treatment duration and relapse.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)